EQNasdaqPharmaceutical PreparationsFiscal year ends December 31

Equillium, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.24+0.05 (+4.20%)

Close on Oct 19, 2026

Market cap: $138.64M
P/E (TTM): –
Dividend yield: –

Equillium, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	–	41	36	16	–	–	–	–	–
Research & Development	13	37	37	38	26	19	18	4.94	–
General & Administrative	11	12	14	17	11	10	9.09	3.67	–
Operating Expenses	24	49	51	78	38	30	27	8.62	–
Operating Income	-24	-8.27	-15	-62	-38	-30	-27	-8.62	–
Interest Expense	–	–	0.49	1.05	1.07	1.10	0.28	2.56	–
Interest & Investment Income	0.83	1.38	2.33	0.42	0.06	0.48	1.39	0.34	–
Other Non-Operating Income	–	–	1.77	-0.35	-1.27	-0.27	1.13	-4.64	–
Gain (Loss) on Sale of Assets	-0.02	0	0	0	0	–	–	–	–
Legal Settlements	0	0	0	0	0	0	0	0	0
Pretax Income	-22	-7.71	-13	-62	-39	-30	-26	-13	–
Income Tax Expense	0	0.36	0.58	0	0	0	–	–	–
Net Income incl. Noncontrolling Interests	-22	-8.07	-13	-62	-39	-30	-26	-13	–
Net Income	-22	-8.07	-13	-62	-39	-30	-26	-13	–
EPS (Basic)(per share)	-0.39	-0.23	-0.38	-1.85	-1.36	-1.46	-1.47	-1.09	–
EPS (Diluted)(per share)	-0.39	-0.23	-0.38	-1.85	-1.36	-1.46	-1.47	-1.09	–
Shares Outstanding (Basic, Weighted)(shares)	57	35	35	34	29	20	17	12	–
Shares Outstanding (Diluted, Weighted)(shares)	57	35	35	34	29	20	17	12	–
EBITDA	–	–	–	-62	-38	-30	-27	-8.61	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -94.0%

Financial strength

Current ratio: 23.40
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2306.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.47
Dividend yield: –